Eugenia Chan, MD, MPH: Treating ADHD During a Pandemic


Dr. Chan said clinical practice guidelines ideally cover about 75% of patients with ADHD.

It is important to continuously update clinical practice guidelines for diseases like attention deficit/hyperactivity disorder (ADHD).

As more and more evidence-based research becomes available, guidelines get updates with the most recent data.

In an interview with HCPLive®, Eugenia Chan, MD, MPH, assistant professor of pediatrics, Harvard Medical School, spoke about the importance of updating clinical practice guidelines for ADHD.

During the annual American Academy of Pediatrics 2021 virtual meeting, Chan discussed some new and update clinical practice guidelines and how they will impact care of this patient population.

But it’s also important to realize clinical practice guidelines will not generally cover every patient with a given disease and there are circumstances that occur outside of the purview of the guidelines.

“It’s important for people to recognize that guidelines aren’t meant to cover 100% of patients,” Chan said. “If they applied to maybe 75% that’s great and that totally depends on how much evidence is out there to support a more detailed guide to treatment.”

Chan also discussed how difficult the pandemic has been for this patient population, particularly those who need routine.

“I think there is no question that the pandemic accelerated mental health crises among children and their parents as well,” Chan said.

Recent Videos
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
© 2024 MJH Life Sciences

All rights reserved.